These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 7566254

  • 1. Erythromycin induced torsades de pointes.
    Wong CB, Windle J.
    Nebr Med J; 1995 Sep; 80(9):285-6. PubMed ID: 7566254
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC, Quasny HA.
    Pharmacotherapy; 1997 Sep; 17(3):626-30. PubMed ID: 9165570
    [Abstract] [Full Text] [Related]

  • 5. Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia.
    de Koning J, van der Hoeven H, Hamer B, Thompson J.
    Neth J Med; 1994 Apr; 44(4):131-5. PubMed ID: 8196823
    [Abstract] [Full Text] [Related]

  • 6. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y, Swartzon M, Justo D.
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin.
    Kyrmizakis DE, Chimona TS, Kanoupakis EM, Papadakis CE, Velegrakis GA, Helidonis ES.
    Am J Otolaryngol; 2002 Apr; 23(5):303-7. PubMed ID: 12239699
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning.
    Chang JH, Weng TI, Fang CC.
    Am J Emerg Med; 2009 Oct; 27(8):1016.e1-3. PubMed ID: 19857426
    [Abstract] [Full Text] [Related]

  • 14. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
    Amankwa K, Krishnan SC, Tisdale JE.
    Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
    [Abstract] [Full Text] [Related]

  • 15. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W.
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [Abstract] [Full Text] [Related]

  • 16. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
    Takahashi N, Ito M, Inoue T, Koumatsu K, Takeshita Y, Tsumabuki S, Tamura M, Inoue K, Maeda T, Saikawa T.
    J Cardiol; 1993 Oct; 23(1):99-106. PubMed ID: 8164140
    [Abstract] [Full Text] [Related]

  • 17. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP.
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.
    Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D.
    Angiology; 1997 Sep; 48(9):821-6. PubMed ID: 9313632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.